| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $501,694 ) |
| | 2024 | 2024 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 000 | 5 | NIH | 11/29/2023 | $339,694 |
| | 2024 | 2024 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | K22CA251643 | Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer | 000 | 3 | NIH | 2/2/2024 | $162,000 |
|
| Issue Date FY: 2023 ( Subtotal = $1,498,815 ) |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 000 | 4 | NIH | 11/29/2022 | $339,694 |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 001 | 4 | NIH | 3/17/2023 | $30,195 |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 10 | NIH | 5/31/2023 | $384,038 |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | K22CA251643 | Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer | 000 | 2 | NIH | 12/22/2022 | $162,000 |
| | 2023 | 2023 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA255650 | Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response | 000 | 2 | NIH | 9/1/2023 | $582,888 |
|
| Issue Date FY: 2022 ( Subtotal = $1,107,205 ) |
| | 2022 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 000 | 3 | NIH | 12/3/2021 | $339,694 |
| | 2022 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 001 | 3 | NIH | 5/24/2022 | $30,195 |
| | 2022 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 9 | NIH | 8/4/2022 | $384,038 |
| | 2022 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | K22CA251643 | Contribution of the Inflammasome to Radiation Response in Pancreatic Cancer | 000 | 1 | NIH | 2/1/2022 | $162,000 |
| | 2022 | 2022 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21CA248904 | Elucidating the role of intratumoral microbiota on immunotherapy efficacy | 000 | 2 | NIH | 7/1/2022 | $191,278 |
| | 2022 | 2021 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA255650 | Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response | 000 | 1 | NIH | 8/18/2022 | $0 |
| | 2022 | 2020 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA208644 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. | 000 | 5 | NIH | 2/8/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,596,609 ) |
| | 2021 | 2021 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 000 | 2 | NIH | 11/18/2020 | $358,565 |
| | 2021 | 2021 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 001 | 8 | NIH | 5/25/2021 | $391,875 |
| | 2021 | 2021 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 001 | 2 | NIH | 2/11/2021 | $18,873 |
| | 2021 | 2021 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA255650 | Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response | 000 | 1 | NIH | 8/2/2021 | $593,078 |
| | 2021 | 2021 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21CA248904 | Elucidating the role of intratumoral microbiota on immunotherapy efficacy | 000 | 1 | NIH | 7/12/2021 | $234,218 |
| | 2021 | 2018 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 5 | NIH | 3/18/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,146,751 ) |
| | 2020 | 2020 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA244142 | Rewiring the myeloid cell response to adjuvants to improve tumor control | 000 | 1 | NIH | 12/2/2019 | $377,438 |
| | 2020 | 2020 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 7 | NIH | 5/6/2020 | $391,875 |
| | 2020 | 2020 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA208644 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. | 000 | 5 | NIH | 8/17/2020 | $377,438 |
| | 2020 | 2017 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21AI126151 | Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses. | 000 | 2 | NIH | 11/16/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $757,989 ) |
| | 2019 | 2019 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA208644 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. | 000 | 4 | NIH | 8/21/2019 | $366,114 |
| | 2019 | 2019 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 6 | NIH | 6/17/2019 | $391,875 |
| | 2019 | 2016 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R03CA198208 | Generation of a novel fusion protein to redirect macrophage differentiation following radiation therapy. | 000 | 2 | NIH | 12/17/2018 | $0 |
| | 2019 | 2016 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21CA190790 | Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma | 000 | 2 | NIH | 12/17/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $120,956 ) |
| | 2018 | 2018 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 5 | NIH | 5/29/2018 | $321,625 |
| | 2018 | 2018 | PROVIDENCE HEALTH & SERVICES - OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA208644 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. | 000 | 3 | NIH | 8/16/2018 | $377,438 |
| | 2018 | 2014 | Providence Health System-Oregon | 4805 NE Glisan St | Portland | OR | 97213-2933 | MULTNOMAH | USA | 1C1CMS330985 | Redesigning Service Delivery through the Tri-County Health Commons | 03 | 3 | CMS | 1/29/2018 | -$578,107 |
| | 2018 | 2013 | Providence Health System-Oregon | 4805 NE Glisan St | Portland | OR | 97213-2933 | MULTNOMAH | USA | 1C1CMS330985 | Redesigning Service Delivery through the Tri-County Health Commons | 03 | 3 | CMS | 1/29/2018 | $0 |
| | 2018 | 2012 | Providence Health System-Oregon | 4805 NE Glisan St | Portland | OR | 97213-2933 | MULTNOMAH | USA | 1C1CMS330985 | Redesigning Service Delivery through the Tri-County Health Commons | 03 | 3 | CMS | 1/29/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $905,313 ) |
| | 2017 | 2017 | PROVIDENCE HEALTH SYSTEM-OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 4 | NIH | 5/23/2017 | $321,625 |
| | 2017 | 2017 | PROVIDENCE HEALTH SYSTEM-OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA208644 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. | 000 | 2 | NIH | 8/30/2017 | $377,438 |
| | 2017 | 2017 | PROVIDENCE HEALTH SYSTEM-OREGON | 4805 NE GLISAN ST | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21AI126151 | Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses. | 000 | 2 | NIH | 5/22/2017 | $206,250 |
|
| Issue Date FY: 2016 ( Subtotal = $1,215,055 ) |
| | 2016 | 2016 | PROVIDENCE PORTLAND MEDICAL CENTER | 4805 NE GLISAN STREET | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA182311 | High dose radiation therapy to direct immune responses to pancreatic cancer | 000 | 3 | NIH | 6/28/2016 | $321,625 |
| | 2016 | 2016 | PROVIDENCE PORTLAND MEDICAL CENTER | 4805 NE GLISAN STREET | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21CA190790 | Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma | 000 | 2 | NIH | 6/16/2016 | $185,992 |
| | 2016 | 2016 | PROVIDENCE PORTLAND MEDICAL CENTER | 4805 NE GLISAN STREET | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R21AI126151 | Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses. | 000 | 1 | NIH | 6/14/2016 | $247,500 |
| | 2016 | 2016 | PROVIDENCE PORTLAND MEDICAL CENTER | 4805 NE GLISAN STREET | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R03CA198208 | Generation of a novel fusion protein to redirect macrophage differentiation following radiation therapy. | 000 | 2 | NIH | 6/15/2016 | $82,500 |
| | 2016 | 2016 | PROVIDENCE PORTLAND MEDICAL CENTER | 4805 NE GLISAN STREET | PORTLAND | OR | 97213-2933 | MULTNOMAH | USA | R01CA208644 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer. | 000 | 1 | NIH | 9/2/2016 | $377,438 |
|
|
